<!DOCTYPE html>
<html>
<head>
<meta http-equiv="X-UA-Compatible" content="IE=Edge" />
<meta charset="utf-8" />
</head>

<body style="margin: 0;">

<div id="p57" style="overflow: hidden; position: relative; background-color: white; width: 908px; height: 1286px;">

<!-- Begin shared CSS values -->
<style class="shared-css" type="text/css" >
.t {
	transform-origin: bottom left;
	z-index: 2;
	position: absolute;
	white-space: pre;
	overflow: visible;
	line-height: 1.5;
}
.text-container {
	white-space: pre;
}
@supports (-webkit-touch-callout: none) {
	.text-container {
		white-space: normal;
	}
}
</style>
<!-- End shared CSS values -->


<!-- Begin inline CSS -->
<style type="text/css" >

#t1_57{left:130px;bottom:1196px;letter-spacing:-0.15px;}
#t2_57{left:804px;bottom:1195px;letter-spacing:0.13px;}
#t3_57{left:238px;bottom:1115px;letter-spacing:-0.01px;}
#t4_57{left:238px;bottom:1096px;letter-spacing:-0.01px;}
#t5_57{left:238px;bottom:1076px;letter-spacing:-0.01px;}
#t6_57{left:238px;bottom:1057px;letter-spacing:-0.01px;}
#t7_57{left:238px;bottom:1037px;letter-spacing:-0.01px;}
#t8_57{left:238px;bottom:983px;letter-spacing:-0.01px;}
#t9_57{left:238px;bottom:964px;letter-spacing:-0.01px;}
#ta_57{left:238px;bottom:944px;letter-spacing:-0.01px;}
#tb_57{left:238px;bottom:925px;letter-spacing:-0.01px;}
#tc_57{left:128px;bottom:852px;letter-spacing:0.16px;}
#td_57{left:238px;bottom:852px;letter-spacing:-0.19px;}
#te_57{left:258px;bottom:823px;letter-spacing:0.18px;}
#tf_57{left:141px;bottom:788px;letter-spacing:-0.1px;}
#tg_57{left:248px;bottom:788px;letter-spacing:-0.01px;}
#th_57{left:141px;bottom:756px;letter-spacing:-0.03px;}
#ti_57{left:250px;bottom:751px;letter-spacing:-0.01px;}
#tj_57{left:250px;bottom:732px;letter-spacing:-0.01px;}
#tk_57{left:250px;bottom:713px;letter-spacing:-0.01px;}
#tl_57{left:143px;bottom:708px;letter-spacing:-0.28px;}
#tm_57{left:248px;bottom:657px;letter-spacing:-0.03px;}
#tn_57{left:248px;bottom:628px;letter-spacing:-0.04px;}
#to_57{left:141px;bottom:556px;letter-spacing:-0.01px;}
#tp_57{left:248px;bottom:556px;letter-spacing:-0.01px;}
#tq_57{left:141px;bottom:524px;letter-spacing:-0.03px;}
#tr_57{left:250px;bottom:519px;letter-spacing:-0.01px;}
#ts_57{left:250px;bottom:500px;letter-spacing:-0.01px;}
#tt_57{left:250px;bottom:481px;letter-spacing:-0.01px;}
#tu_57{left:143px;bottom:476px;letter-spacing:-0.3px;}
#tv_57{left:250px;bottom:452px;letter-spacing:-0.01px;}
#tw_57{left:248px;bottom:416px;letter-spacing:-0.03px;}
#tx_57{left:248px;bottom:386px;letter-spacing:-0.04px;}
#ty_57{left:141px;bottom:315px;letter-spacing:-0.01px;}
#tz_57{left:248px;bottom:315px;letter-spacing:-0.01px;}
#t10_57{left:141px;bottom:283px;letter-spacing:-0.03px;}
#t11_57{left:250px;bottom:278px;letter-spacing:-0.01px;}
#t12_57{left:250px;bottom:259px;letter-spacing:-0.01px;}
#t13_57{left:250px;bottom:239px;letter-spacing:-0.01px;}
#t14_57{left:143px;bottom:235px;letter-spacing:-0.3px;}
#t15_57{left:250px;bottom:211px;letter-spacing:-0.01px;}
#t16_57{left:248px;bottom:175px;letter-spacing:-0.03px;}
#t17_57{left:248px;bottom:141px;letter-spacing:-0.04px;}
#t18_57{left:202px;bottom:69px;letter-spacing:0.23px;}

.s0_57{font-size:11px;font-family:NotoSans-Regular_7j-;color:#000;}
.s1_57{font-size:12px;font-family:NotoSans-Regular_7j-;color:#000;}
.s2_57{font-size:13px;font-family:NotoSans-Regular_7j-;color:#000;}
.s3_57{font-size:21px;font-family:NotoSans-Regular_7j-;color:#000;}
.s4_57{font-size:18px;font-family:NotoSans-Regular_7j-;color:#000;}
.s5_57{font-size:14px;font-family:NotoSans-Regular_7j-;color:#000;}
.s6_57{font-size:10px;font-family:NotoSans-Regular_7j-;color:#000;}
.s7_57{font-size:28px;font-family:NotoSans-Regular_7j-;color:#000;}
</style>
<!-- End inline CSS -->

<!-- Begin embedded font definitions -->
<style id="fonts57" type="text/css" >

@font-face {
	font-family: NotoSans-Regular_7j-;
	src: url("fonts/NotoSans-Regular_7j-.woff") format("woff");
}

</style>
<!-- End embedded font definitions -->

<!-- Begin page background -->
<div id="pg57Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg57" style="-webkit-user-select: none;"><object width="908" height="1286" data="57/57.svg" type="image/svg+xml" id="pdf57" style="width:908px; height:1286px; -moz-transform:scale(1); z-index: 0;"></object></div>
<!-- End page background -->


<!-- Begin text definitions (Positioned/styled in CSS) -->
<div class="text-container"><span id="t1_57" class="t s0_57">7.3. Fundamental considerations of multimodal therapy approaches </span><span id="t2_57" class="t s1_57">57 </span>
<span id="t3_57" class="t s2_57">Patients, 85% of T2 patients and 94% of T3 patients [182]. In a prospective observational study </span>
<span id="t4_57" class="t s2_57">of 24 patients with T3 supraglottic carcinomas, Pantazis et al. determined a 5-year disease- </span>
<span id="t5_57" class="t s2_57">specific survival of 91.7% and a laryngeal preservation of 91.7% [183]. In a retrospective </span>
<span id="t6_57" class="t s2_57">observational study of 43 patients with supraglottic carcinomas (23 stage I–II and 20 stage III– </span>
<span id="t7_57" class="t s2_57">IV), Breda et al. reported a laryngeal preservation of 90.7% [184]. </span>
<span id="t8_57" class="t s2_57">In conclusion, it is stated that T1/T2 carcinomas of the subglottis are very rare and, due to </span>
<span id="t9_57" class="t s2_57">their particularly aggressive nature, laryngectomy is generally recommended. Systematic </span>
<span id="ta_57" class="t s2_57">survival data are sparse and generally indicate a worse prognosis than glottic and </span>
<span id="tb_57" class="t s2_57">supraglottic carcinomas. </span>
<span id="tc_57" class="t s3_57">7.3. </span><span id="td_57" class="t s3_57">Fundamental considerations of multimodal </span>
<span id="te_57" class="t s4_57">Therapy approaches </span>
<span id="tf_57" class="t s5_57">7.9. </span><span id="tg_57" class="t s2_57">Evidence-based statement </span>
<span id="th_57" class="t s6_57">Level of Evidence </span>
<span id="ti_57" class="t s2_57">In patients with locally advanced (non-metastatic) laryngeal carcinoma (stage III - IVA), </span>
<span id="tj_57" class="t s2_57">locoregional tumor control and overall survival are statistically significantly better after </span>
<span id="tk_57" class="t s2_57">primary chemoradiotherapy than after radiotherapy alone. </span>
<span id="tl_57" class="t s7_57">1a </span>
<span id="tm_57" class="t s6_57">[185-188] </span>
<span id="tn_57" class="t s6_57">Strong consensus: 100% </span>
<span id="to_57" class="t s2_57">7.10. </span><span id="tp_57" class="t s2_57">Evidence-based statement </span>
<span id="tq_57" class="t s6_57">Level of Evidence </span>
<span id="tr_57" class="t s2_57">Locoregional tumor control after simultaneous chemoradiotherapy is better than after </span>
<span id="ts_57" class="t s2_57">neoadjuvant chemotherapy followed by radiotherapy or surgical therapy in case of non- </span>
<span id="tt_57" class="t s2_57">response to neoadjuvant chemotherapy. </span>
<span id="tu_57" class="t s7_57">1b </span>
<span id="tv_57" class="t s2_57">The overall survival is the same. </span>
<span id="tw_57" class="t s6_57">[187, 188] </span>
<span id="tx_57" class="t s6_57">Strong consensus: 100% </span>
<span id="ty_57" class="t s2_57">7.11. </span><span id="tz_57" class="t s2_57">Evidence-based statement </span>
<span id="t10_57" class="t s6_57">Level of Evidence </span>
<span id="t11_57" class="t s2_57">Locoregional tumor control is better after laryngectomy followed by radiotherapy </span>
<span id="t12_57" class="t s2_57">than after neoadjuvant chemotherapy followed by radiotherapy alone and, if </span>
<span id="t13_57" class="t s2_57">necessary, salvage laryngectomy. </span>
<span id="t14_57" class="t s7_57">1b </span>
<span id="t15_57" class="t s2_57">The overall survival is the same. </span>
<span id="t16_57" class="t s6_57">[187-189] </span>
<span id="t17_57" class="t s6_57">Strong consensus: 100% </span>
<span id="t18_57" class="t s0_57">© Oncology Guideline Program | S3 Guideline Laryngeal Carcinoma | Long Version 1.0 | January 2019 </span></div>
<!-- End text definitions -->


</div>
</body>
</html>
